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Abstract
Introduction: Dietary control of classic phenylketonuria (PKU) needs restriction
of natural proteins; adequate protein intake is achieved by adding low
phenylalanine (phe) formulae. The adequacy of this diet for normal bone
mineralization had not been sufficiently evaluated. Our aim was to evaluate
and follow up bone mineral density (BMD) in children and adolescents with PKU
within a 2-year time interval to assess the adequacy of a phenylalanine restricted
diet for bone mineralization and to search for a possible relationship between
BMD, dietary control and blood phenylalanine (phe) concentrations. 
Material and methods: Thirty-two patients with classic PKU (3-19 years) were
evaluated for their bone mineral status using dual energy X-ray absorptiometry
(DEXA) both at the beginning (baseline) and the end (follow-up) of the study. 
Results: Low BMD was detected in 31.25% at the start and in 6.25% of patients
after 2 years follows-up. No relationship was found between BMD and the
duration of diet compliance and phe level as well.
Conclusions: In this study the low BMD detected in our patients was both at
baseline and follow-up independent of diet restriction. A yearly DEXA would be
highly beneficial for early detection and treatment, thus preventing osteoporosis
and decreasing the risk of fractures. We also suggest the importance of searching
for new emerging therapies such as enzyme substitution or gene therapy as
low protein diet compliance was not enough to maintain normal bone mineral
density.
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Introduction
Phenylketonuria (PKU) is one of the first characterized metabolic diseases.
Untreated PKU leads to mental retardation. Classical PKU results from
impaired activity of the liver enzyme phenylalanine hydroxylase, which
converts phenylalanine (phe) to tyrosine [1]. The advent of neonatal screening
for PKU has enabled the start of a low phenylalanine diet early in life and
the prevention of intellectual retardation associated with the disease [2].
Osteoporosis is increasingly being recognized in paediatric practice as
a consequence of several factors including the increasing complexity of
chronic conditions [3]. Several studies have suggested an increased risk
of fractures [4] or a defect in bone mineralization in adults, adolescents
and children with PKU [2, 5-13].
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Copyright © 2011 Termedia & BanachThe aim of this study was to evaluate and follow
up bone mineral density (BMD) in children and
adolescents with PKU within a 2-year time interval
to assess the adequacy of a phenylalanine res  -
tricted diet for bone mineralization and to search
for a possible relationship between BMD, dietary
control, and blood phenylalanine (phe) concen  -
trations.
Material and methods
Our study included 32 patients with phenyl  -
ketonuria recruited from the Association of Genetic
and Metabolic Disorders and studied in the paediatric
clinic of the National Research Centre (NRC).
Nineteen males and thirteen females were
diagnosed clinically by fair hair and complexion, and
developmental and mental retardation. A history of
an affected sibling diagnosed with PKU developed
the awareness in families to seek neonatal
diagnosis. The diagnosis was confirmed by measu  -
re  ment of the blood phe level. The mean age of the
patients was 8.6 ±4.7 years, and at the end of the
study was 10.7 ±4.9 years. The study period was
from January 2007 to January 2009. The selected
patients were receiving a low protein diet consisting
of low protein breads and pastas (wheat starch,
Metamucil and methylcellulose), phenyl  ala  nine free
formulas, fresh fruits and vegetables [14]. 
A control group of 42 age- and sex-matched
Egyptian children was also included in the study.
Informed consent was obtained from the parents
of the children according to the guidelines of the
ethical committee of NRC, Dokki, Egypt.
All patients were subjected to the following:
detailed history and clinical examination including
pedigree analysis noting the presence of consan  -
guinity and family history of (PKU), age of diagnosis
and duration of diet compliance, pattern of
compliance (off diet, irregular or continuous
compliance), and developmental milestones
(namely: age of head support, mother recognition,
sitting ,walking, and age of speech) [15]. The follow-
up clinical visit for each patient was monthly,
monitoring the growth status, phe level and diet
compliance; diet adherence was determined based
on the patient’s report. Meticulous chest, heart,
abdomen, and neurological examinations were
done throughout the study period. 
Anthropometric measurements: The weight was
measured to the nearest 0.1 kg with a digital
balance and with the patients in light clothes and
without shoes. Height was measured to the nearest
0.5 cm with a stadiometer. Body mass index was
calculated as weight divided by height squared for
each patient (kg/m2). These parameters were
adjusted to age and compared to Egyptian and 
CDC (Centre for Disease Control and Prevention)
reference growth values and taken twice at the
same time of each DEXA with statistical comparison
between the 2 readings [16]. 
Bone mineral density and bone mineral content
(BMC) were checked by dual-energy x-ray absorp  -
tiometry (DEXA) [17]. The Norland densitometer 
(XR-46, USA) Rev. 3.9.6/2.3.1 was used for BMD
assessment. Oral sedation was required in 10
patients and the maximum time required for each
evaluation was about 15 min. Bone mineral density
for each patient was expressed in g/cm2 and BMC
in g, both from the lumbar vertebrae (L2-L4) and the
femoral neck. Results were expressed as Z-score,
the standard deviation (SD) from normal mean
BMD for an age- and sex-matched Egyptian
paediatric population. An abnormal DEXA was
defined as more than one SD below the normal
mean, expressed as Z-score < –1. Low BMD
(osteopenia) was defined as Z-score from –1 to –2;
very low BMD (severe osteopenia) was defined as
Z-score from –2 to –2.5 and osteoporosis < –2.5 or
spontaneous fracture [13, 18]. The DEXA was done
at baseline and follow-up study with statistical
comparison between them. 
Blood phenylalanine level was measured
monthly by ELISA using the dried blood spot test.
The mean of the two readings was recorded at the
time of each DEXA with statistical comparison
between them. 
Statistical analysis
The results were computerized and analysed
statistically using SPSS version 14.0. Results were
expressed as means ± standard deviation (SD).
Independent t-test was used to compare between
two groups and analysis of variance test (ANOVA)
was used for the comparisons between more than
two groups. Paired t-test was used to detect the
changes in the quantitative data after diet for 
2 years. Pearson correlation coefficient was used
to determine the relationships between the
quantitative variables. The level of significance was
considered at p-value < 0.05.
Results 
The comparison between patients and controls
at the start of this study for age, weight, height,
body mass index (BMI), weight for age Z-score
(WAZ), height for age Z-score (HAZ) and BMI
percentiles is displayed in Table I. The WAZ and HAZ
were significantly lower than controls (p < 0.005).
Regarding the BMI percentile a statistical
comparison was done between the Egyptian and
CDC percentiles and the difference was not
statistically significant (mean 50.4 ±5.18 and 59.2
±5.20 respectively in 2007; mean 62.2 ±4.17 
and 70 ±4.58 respectively in 2009). The p value in
both was > 0.05.
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The different parameters of the first DXA
(patients and controls) are shown in Table II.
A significant statistical difference was present in
the femoral neck bone mineral density (FN-BMD),
FN Z-score, and lumbar spine (L2-L4) Z-score, where
the patients were significantly lower than the
controls. The other parameters were also lower than
controls but not statistically significant. 
The comparison between the first and follow-up
evaluation of growth and phe level is presented in
Table III, showing a significant catch up of growth
between the two readings except HAZ, in which
improvement did not reach statistical significance.
No significant statistical difference regarding the
blood phe level was found.
The baseline and follow-up DXA are compared
in Table IV, showing a significant statistical increase
in all parameters except the lumbar Z-score, where
p > 0.05.
No correlation was found between growth (WAZ,
HAZ) and phenylalanine (phe) levels and duration
of diet compliance as well. Also no correlation was
found between the blood phe level and BMD or
BMC in both evaluations.
The age of the patients at baseline and follow-
up was positively correlated with the mean femoral
and lumbar BMD, being r = 0.7, p ≤ 0.0001 and 
r = 0.9, p ≤ 0.0001 respectively. A significant inverse
negative correlation was present between the age
of the patients and the lumbar ( L2-L4) Z-score in
Parameters Type N Mean SD t-Test Value of p
Age [years] PT 32 8.6 4.7 0.036 NS
C 42 8.6 3.9
Weight [kg] PT 32 28.2 2.43 1.405 NS
C 42 33.0 2.41
Height [cm] PT 32 121.8 4.20 1.302 NS
C 42 128.4 2.89
HAZ PT 32 –0.95 0.2 2.947 < 0.005
C 42 –0.17 0.18
WAZ PT 32 –0.3 0.22 3.032 < 0.005
C 42 0.61 0.2
BMI [kg/m2] PT 32 17.8 0.49 1.454 NS
C 42 19.0 0.64
BMI_percentile_Egypt PT 32 50.4 5.18 1.752 NS
C 42 61.5 3.88
BMI_percentile_CDC PT 32 59.2 5.20 1.774 NS
C 42 70.6 3.96
Table I. Comparison of growth between patients and controls (first evaluation)
Parameters Type N Mean SD t-Test Value of p
FN_BMD [gm/cm2] PT 32 0.6 0.03 3.753 < 0.0001
C 42 0.7 0.02
FN_BMC [gm] PT 32 2.0 0.18 1.833 NS
C 42 2.5 0.17
FN_Z-score PT 32 –0.7 0.12 5.421 < 0.0001
C 42 0.03 0.08
BMD_L2_L4 PT 32 0.5 0.03 1.56 NS
C 42 0.6 0.02
BMC_L2_L4 PT 32 14.9 1.65 1.239 NS
C 42 17.4 1.29
Z-score_L2_L4 PT 32 –0.4 0.12 2.638 0.01
C 42 0.1 0.11
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N Mean SD Paired t-test Value of p
Weight_2007  32 28.2 2.43 11.653 < 0.0001
Weight_2009 32 35.5 2.67
Height_2007 32 121.8 4.20 14.337 < 0.0001
Height_2009 32 132.5 3.91
BMI_2007 32 17.8 2.75 5.443 < 0.0001
BMI_2009 32 19.2 3.06
BMI_percentile_CDC_2007 32 59.2 5.20 2.797 < 0.01
BMI_percentile_CDC_2009 32 70.3 4.58
Egyptian BMI percentile 2007 32 51.8 5.13 2.479 < 0.05
Egyptian BMI percentile 2009 32 62 4.17
WAZ 2007 32 –0.29 0.22 3.116 < 0.005
WAZ 2009 32 1.12 0.57
HAZ 2007 32 –0.95 2 1.306* NS
HAZ 2009 32 0.18 0.65
Phe [mg/dl] 2007 32 12.3 0.95 0.8 NS
Phe [mg/dl] 2009 32 11.7 0.98
Table III. Growth and Phe comparison at baseline and follow-up study
*Wilcoxon signed ranks test (Z-test)
N Mean SD Paired t-test Value of p
FN_BMD 2007 32 0.6 0.03 8.97 < 0.0001
FN_BMD 2009 32 0.7 0.02
FN_BMC 2007 32 2.0 0.18 5.048 < 0.0001
FN_BMC 2009 32 2.4 0.19
FN_Z-score_2007 32 –0.7 0.12 2.777 < 0.01
FN_Z-score_2009 32 –0.5 0.10
BMD_L2_L4_2007 32 0.5 0.03 9.959 < 0.0001
BMD_L2_L4_2009 32 0.6 0.03
BMC_L2_L4_2007 32 14.9 1.65 9.312 < 0.0001
BMC_L2_L4_2009 32 19.1 1.82
Z-score_L2_L4_2007 32 –0.4 0.12 1.378 NS
Z-score_L2_L4_2009 32 –0.2 0.10
Table IV. Bone mineral status at baseline and follow-up study
2009 (r = –0.4, p ≤ 0.05). No correlation was found
between the duration of dietary compliance and
lumbar and femoral BMD and its Z-scores in both
evaluations. The individual progression of the
femora and lumbar Z-scores on both occasions is
shown in Figures 1 and 2 and Table V. It can be seen
that femoral BMD Z-score declined in 9/32 patients
(28%); 4/9 were off diet, 3/9 were irregularly
compliant and 2/9 were strictly diet adherent; for
the lumbar area 11/32 patients (34.37%) had
a decreased lumbar Z-score; 4/11 were off diet, 
3/11 strictly diet adherent, and 4/11 were irregularly
compliant. 
At baseline, femoral osteopenia was present in 10
patients (31.25%) and 3/10 had osteopenia of the
lumbar area as well; 5/10 were under the age of 
7 years, and the other 5/10 aged from 9 to 
16 years. Five (5/10) patients were on a strict diet, 3/10
were off diet, and 2/10 were irregularly compliant. At
follow-up, improvement with an increase in Z-score
was present in all 10 patients. Another 2 pa  tients
(6.25%), 19 and 21 years old, were not osteopenic at
the start of the study but developed osteopenia (–1.11
and –1.8) at the end of the study. 
Among the osteopenic patients 5/10 were given
oral drug supplement (calcium + vitamin D3) in
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addition to diet control and showed an
improvement of their BMD Z-score from –1.7, –1.63,
–1.29, –1.50, and –1.10 in the first evaluation to –
0.43, –0.76, –0.41, –1.17, and –0.72 in the second
evaluation. Only one patient remained osteopenic.
The rest of osteopenic patients refused to take the
drug supplement and showed a slower rate of
improvement from –2.02, 1.56, –1.01, –1.42, –1.63 to
–1.05, –1.22, –0.7, –1.2, –1.4. Four patients remained
in the osteopenic region.
Clinically, there was a delay in the different
developmental milestones in the group of patients,
with mean age of head support 1.2 ±0.93 years, age
of mother recognition 1.6 ±1.6 years, age of sitting
1.3 ±0.95 years, age of walking 2.6 ±1.3 years. The
duration of diet compliance (mean 2.3 ±2.1 years)
was associated with a significant inverse negative
correlation with the blood phe level both at the start
and follow-up (r = –0.05, p < 0.001 and r = –0.05, 
p < 0.005) respectively. The mean age of diagnosis
was 1.8 ±1.4 years (1 week-4 years); 9 patients were
diagnosed early (the first 6 months of life); 5 of
them were diagnosed in the neonatal period
(positive history in a sib); 4 of those 5 were on
a strict low protein diet and are mentally normal,
attending regular schools.
Concerning the pattern of patient compliance,
11 of them (34.37%) were not compliant (off diet),
12 (37.5%) were partially compliant with some
period of relaxation (irregular pattern) and 
9 (28.12%) had a strict continuous pattern of
compliance. The age of speech for the 3 groups
was: no speech present in the off-diet group (only
a few words), 1.8 ±0.40 years in the irregular group
and 2 ±0.78 years in the continuous group. 
The blood phe levels showed a significant
statistical difference between the 3 groups, where
the smallest value was in the continuously
compliant group; in 2007 the mean was 16.4 
±1.15 mg/dl in the off group, 13 ±0.94 mg/dl in the
irregular group and 6.3 ±1.2 mg/dl in the
continuously compliant group (F-ratio = 20.572, 
p ≤ 0.0001). In 2009, the mean was 14.6 ±1.32 mg/dl
in the off group, 14.2 ±1.01 mg/dl in the irregular
group and 4.9 ±0.75 mg/dl in the continuously
compliant group (F-ratio 23.214, p ≤ 0.0001).
A marked improvement of milestones and
symptoms with diet (as reported by the patients)
was noted in the compliant groups, both irregular
and continuous (e.g. mother recognition, sitting,
walking, and speech). No statistically significant
difference was found between the 3 groups
regarding the femoral and lumbar BMD and BMC
together with their Z-scores.
Neurological examination at the start of the
study was normal in most patients apart from
hypotonia, which was detected in only one patient
(3.33%), hypertonia in 4 patients (12.5%) and
exaggerated knee jerk in only one patient (3.33%).
These signs disappeared by the end of the study
except the hypotonia, which remained in the same
patient (off diet). Examination of other systems
revealed no abnormality. 
Discussion
With any dietary manipulation involving
elimination of key nutrients as in PKU it is essential
that the replacement therapy is adequate to ensure
normal growth and that the patients are monitored
long term for adverse effects [2]. Our results
confirmed the reduced bone mineralization in
children and adolescents with PKU compared with
controls as reported by other authors [2, 7, 9, 11-13],
who confirmed the lower BMD in children and
adolescents with classical PKU on a standard
dietary regime. The mean femoral and lumbar BMD
Z-scores were significantly lower than the controls
and osteopenia was detected in 31.25% of our
patients in the femoral neck. These findings were
similar to those of Modan-Moses (2007) [13], who
found osteopenia in at least one skeletal site in
38.7% of his patients and reported that trabecular
bone mass as represented by the femoral neck
density was severely affected. In contrast to the
findings of Modan-Moses [13] none of our patients
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Figure 1. Femoral Z-score at baseline and follow-up
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Figure 2. Lumbar Z-score at baseline and follow-up
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had osteoporosis with BMD Z-score < –2.5. The
current study was done on children and adolescents
with PKU, while his study included adult PKU
patients with a mean age of 25 ±5.3 years [13]. The
difference may also be related to different
geographical areas, as reported by Cowell (1995)
[19], who evaluated 24 PKU patients (1-20 years) in
his geographical area for osteopenia, but no
abnormalities in lumbar BMD were found. 
Vitamin and trace element deficiency may
contribute to osteopenia in PKU patients, although
phe-free protein formulas are enriched with
vitamins, minerals and trace elements; iron and B12
depletion as well as low zinc and selenium levels
have been reported in PKU patients. Furthermore,
calcium, folate, thiamine, niacin, and vitamin B6
intake may be up to 60% lower than the
recommended amounts in this patient group [20],
which was confirmed by our results where half of
the osteopenic patients were on a strict low protein
diet with adequate formula intake.
The follow-up DEXA showed declined femoral
and lumbar Z-scores in 28% and 34.4% of patients,
respectively, almost equally to our three groups of
diet compliance. These different patterns of
compliance in relation to BMD proved, as found by
other authors [21, 22], that diet control of PKU
patients is difficult and hypomineralization in those
patients needs to be clarified [13]. Furthermore, the
numbers of patients who decide to stop dietary
treatment increases gradually with age [23].
Half of the osteopenic patients were given oral
calcium and vitamin D supplement and showed
improvement of their BMD Z-score more than those
who did not take the supplement. This was
supported by Pérez-Duen ~as (2002) [10], who found
improvement of BMD of six PKU patients with a low
dose of vitamin D. In addition, these patients were
improved due to adequate sun exposure as the
main source of vitamin D in Mediterranean countries
is cutaneous synthesis from UV radiation [10].
Although the osteopenia was detected first in
the femoral neck, we, like other authors [5], found
a significant negative correlation of lumbar BMD 
Z-score with age, indicating that the lumbar spine
is more prone to the development of osteopenia
and/or osteoporosis with age. BMD measured by
DEXA in the lumbar spine was the technique of
choice for most authors because it has a high
precision  in vivo and permits monitoring of
treatment in the lumbar spine, which is a very
sensitive area for changes in BMD [2, 8, 12].
Data about the relation of BMD to diet are
conflicting; as reported by other authors [10, 12],
we found no correlation between BMD and dietary
control, reflected either by blood phe concentrations
or the duration of compliance; however, other
investigators reported that lack of dietary
compliance and phe level > 19.8 mg/dl were
associated with a decrease in BMC [9]. Many
patients in the present study showed variation in
blood phe level; this was in keeping with Barat
(2002), who suggested that this variation may
contribute to osteopenia in PKU patients [6]. Zeman
et al. (1999) suggested that mutations in the
phenylalanine hydroxylase gene might inherently
predispose PKU patients to osteoporosis although
the potential mechanism for this is unknown [12],
which was nearly in agreement with our study, in
which we could not identify any specific causative
factor for osteopenia.
At the start of the study growth retardation was
observed in our PKU patients in comparison with
controls, like Dobbelaere (2003), who found his PKU
patients shorter and lighter than the reference
population [24]. European studies [25-29] found
similar growth retardation during the first years of
life followed by restoration of the normal growth
curve from the second year or later, supporting our
results that 65.6% of the patients were under 10
years of age and all of them showed a significant
catch up of growth at the follow-up study. In
agreement with other authors, we found no
correlation between phe levels and growth [24, 25,
30, 31]. However, it is clear that the outcome of
growth in PKU patients depends on the therapeutic
approach, genetic background and novel alimentary
substitutes. An international study comparing and
evaluating these differences between centres would
be extremely interesting [24].
Ranks N Wilcoxon signed ranks test
Z test Sig
FN_Z-score_2007 - FN_Z-score_2009   Negative ranks 9 2.656 < 0.01
Positive ranks 23
Ties 0
Z-score_L2_L4_2007 - Z-score_L2_L4_2009 Negative ranks 11 1.45 NS
Positive ranks 19
Ties 2
Table V. Femoral and lumbar Z-scores of the baseline and follow-up study 
Positive ranks – improvement, negative rank – declined Z-score, Ties – no change
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Although delayed developmental milestones
were observed in our patients mostly due to delay
in age of diagnosis, a phenylalanine restricted diet
was introduced immediately after diagnosis as it
may reduce the burden of disabilities even at a late
stage [32-34].
In conclusion, a compromised bone mineral
density was detected at baseline and follow-up
study in our patients; potential contributing factors
include dietary deficiency of protein, calcium,
vitamin D or trace elements or a primary defect in
bone turnover inherent to the disease itself; our
data do not favour any one particular factor. 
We suggest further large-scale studies to
illustrate the mechanism of low BMD in PKU
patients together with annual follow-up DEXA for
early detection and treatment to prevent
osteoporosis and decrease the risk of fractures later
in life. Moreover, and since low BMD was detected
both at baseline and follow-up studies, we
recommend the importance of searching for new
emerging therapies such as enzyme substitution
or gene therapy since low protein diet compliance
was not sufficient to maintain normal bone mineral
density.
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